2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes

Salt Lake City, UT US
October 7, 2022 to October 8, 2022

The 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of implications of actionable molecular alterations across common malignancies.

Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2022 ASCO Annual Meeting in June 2022.

This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.

Call For abstract

Abstract submission deadline: August 19, 2022

Submit to one of the following categories:

  1. Basic science research
  2. Clinical research
  3. Quality-of-care research
  4. Outcomes research
  5. Case reports and case-series

Abstract decisions will be emailed to the first author by August 26, 2022

Click here to submit abstracts

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

 

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand appropriate timing of testing to detect these abnormalities.
  • Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for cancer patients.
Course summary
Available credit: 
  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.
Course opens: 
04/27/2022
Course expires: 
11/08/2022
Event starts: 
10/07/2022 - 3:00pm PDT
Event ends: 
10/08/2022 - 4:30pm PDT
Cost:
$350.00

FRIDAY, OCTOBER 7TH, 2022

1:00 PM                              Registration


2:00 PM to 3:30 PM           Abstract Session 1


3:45 PM to 4:00 PM           Welcome note from the conference chair - Neeraj Agarwal, MD


4:00 PM to 5:00 PM          Session 1: Methods in Precision Oncology 
Moderator: Christos Vaklavas, MD
4:00 PM to 4:15 PM           Next generation sequencing for identification of molecular targets - James Ford, MD
4:15 PM to 4:30 PM           Beyond sequencing – methods in identifying tumor biomarkers for targeted therapies - Vivek Subbiah, MD
4:30 PM to 4:45 PM           Germline genetic testing for cancer prevention and treatment - Siddhartha Yadav, MD
4:45 PM to 5:00 PM           Clinical utility of circulating tumor DNA in cancer treatment - Manish Kohli, MD
5:00 PM to 5:15 PM           Q and A/Panel discussion - Christos Vaklavas, MDJames Ford, MD, Vivek Subbiah, MD, Siddhartha Yadav, MD, and Manish Kohli, MD


5:20 PM to 6:05 PM           Session 2: Somatic and germ line testing: real world challenges 
Moderator Sid Yadav, MD, FACP
5:20 PM to 5:35 PM           Challenges and solutions with somatic genetic testing: what is needed - Beverly Chigarira, MS
5:35 PM to 5:50 PM           Challenges and solutions with germline testing - Amanda Gammon, MS, GCG
5:50 PM to 6:05 PM           Panel discussion - Sid Yadav, MD, Beverly Chigarira, MS, Amanda Gammon, MS, GCG, and Kristen Pauley, MS, CGC


6:15 PM to 8:15 PM           Dinner & Abstract Session 2


SATURDAY, OCTOBER 8TH, 2022

7:00 AM to 7:30 AM           Breakfast and registration


7:30 AM to 8:45 AM           Session 3: Precision oncology in breast and ovarian cancer
Moderator: Paolo Tarantino, MD                   
7:35 AM to 7:50 AM           Precision oncology in metastatic breast cancer - Mark Pegram, MD
7:50 AM to 8:05 AM           Non-metastatic breast cancer - Christos Vaklavas, MD
8:05 AM to 8:20 AM           Key concepts on precision in gynecological malignancies - Theresa Werner, MD 
8:20 AM to 8:50 AM           Panel discussion - Paolo Tarantino, MD, Mark Pegram, MD, Christos Vaklavas, MD, and Theresa Werner, MD


8:50 AM to 10:05 AM           Session 4: Precision Oncology in Lung Cancer
Moderator: Joseph Rosales, MD                   
8:50 AM to 9:05 AM           Metastatic lung cancer - Katie Kerrigan, DO        
9:05 AM to 9:20 AM           Adjuvant treatment of lung cancer - Aaron Mansfield, MD
9:20 AM to 10:05 AM         Panel discussion - Joseph Rosales, MD, Katie Kerrigan, DO, and Aaron Mansfield, MD


10:05 AM to 10:20 AM           Break


10:20 AM to 11:20 AM           Session 5: Precision Oncology in GI Malignancies
Moderator: David Zhen, MD     
10:20 AM to 10:35 AM           Precision Oncology in Colon cancer - Stacey Cohen, MD
10:35 AM to 10:50 AM           Hepatobiliary and pancreatic malignancies - Chris Nevala-Plagemann, MD
10:50 AM to 11:20 AM           Panel based discussion - David Zhen, MD, Stacey Cohen, MD, and Chris Nevala-Plagemann, MD


11:20 AM to 12:20 PM           Session 6: Precision oncology in prostate cancer
Moderator: Daniel Isaac, DO                          
11:20 AM to 11:35 AM           Precision oncology in metastatic prostate cancer - Benjamin Maughan, MD
11:35 PM to 11:50 PM           Precision oncology in metastatic bladder cancer - Sumati Gupta, MD
11:50 PM to 12:20 PM           Panel based discussion - Daniel Isaac, DO, Benjamin Maughan, MD, Sumati Gupta, MD, Umang Swami, MD, Beverly Chigarira, and Neeraj Agarwal, MD


12:20 PM to 1:15 PM           Lunch


1:15 PM to 2:15 PM           Session 7: Precision oncology in hematological malignancies
Moderator: Srinivas Tantravahi, MBBS
1:20 PM to 1:35 PM           Precision oncology in acute leukemias - Tibor Kovacsovics, MD
1:35 PM to 1:50 PM           Precision oncology in multiple myeloma - Douglas Sborov, MD, MS
1:50 PM to 2:15 PM           Panel discussion – Srinivas Tantravahi, MBBS, Tibor Kovacsovics, MD, and Sagar Patel, MD


2:15 PM to 3:15 PM           Session 8: Precision medicine: perspectives from molecular pathologists
Moderator: Anna Matynia, MD
2:15 PM to 2:20 PM           Introduction 
2:20 PM to 2:35 PM           Pre-Analytical Variables and Precision Oncology: How we can improve our Patient Management - Deepika Sirohi, MD
2:35 PM to 2:50 PM           Critical Role of Molecular Pathologist in Precision Oncology - Allie Grossmann, MD, PhD
2:50 PM to 3:15 PM           Panel discussion - Anna Matynia, MD, Deepika Sirohi, MD, Allie Grossmann, MD, PhD, and JongTaek Kim, MD, MS


3:15 PM to 3:30 PM           Break


3:30 PM to 4:30 PM           Session 9: Implementation science in precision oncology
Moderator: Dr. Neeraj Agarwal
3:30 PM to 3:45 PM           Disparities in precision oncology and improving access to evidence-based testing for targeted therapies - Jack West, MD
3:45 PM to 4:00 PM           Strategies for clinical implementation of precision oncology - Howard L. McLeod, Pharm.D., FASCO, FCCP
4:00 PM to 4:30 PM           Panel discussion -Neeraj Agarwal, MDJack West, MD, Howard L. McLeod, Pharm.D., FASCO, FCCP, Soffe Timm, RN, and Jennifer Lloyd, ARNP 


4:30 PM           Concluding remarks - Neeraj Agarwal, MD

 

Hilton Salt Lake City Center
255 S W Temple
Salt Lake City, UT 84101
United States

A limited number of rooms have been reserved for the attendees of this conference at the Hilton Salt Lake City Center at the discounted rate of $234 per night. To book a room, please go to https://book.passkey.com/e/50271656.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Committee member(s)

Daniel Isaac

has no relevant financial relationships to disclose at this time.
Course Director(s)

Theresa Werner, MD

has a financial relationship (Other) with Mersana Therapeutics;.
Moderator(s)

Daniel Isaac

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with Novartis;.

Paolo Tarantino, MD

has a financial relationship (Professional Services) with AstraZeneca;.

David Zhen, MD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Daiichi-Sankyo;.
has a financial relationship (Grant Or Contract) with SeaGen;.
Speaker(s)

Beverly Chigarira

has no relevant financial relationships to disclose at this time.

Stacey Cohen

has a financial relationship (Independent contractor) with Taiho;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Delcath;.
has a financial relationship (Independent contractor) with Kallyope;.
has a financial relationship (Independent contractor) with Proventus - Isofol;.

James Ford, MD, FASCO

has no relevant financial relationships to disclose at this time.

Allie Grossmann, MD PhD

has a financial relationship (Employment) with Merck;.

Sumati Gupta, MD

has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Acrotech;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with LSK;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Stock Options) with Salarius;.
has a financial relationship (Grant Or Contract) with QED;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Clovis;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Rexahn;.
has a financial relationship (Grant Or Contract) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.

Katie Kerrigan, DO

has no relevant financial relationships to disclose at this time.

Manish Kohli

has a financial relationship (Independent contractor) with Bristol Meyer Squibb/Celgene;.
has a financial relationship (Independent contractor) with Genapsys Inc.;.

Jennifer Lloyd

has no relevant financial relationships to disclose at this time.

Aaron Mansfield, M.D.

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with TRIPTYCH Health Partners;.
has a financial relationship (Professional Services) with Answers in CME;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Rising Tide;.
has a financial relationship (Professional Services) with Intellisphere;.
has a financial relationship (Other) with Mesothelioma Applied Research Foundation;.
has a financial relationship (Travel) with Roche;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Chugai Pharmaceutical Co Ltd (Roche);.
has a financial relationship (Professional Services) with Miami Mesothelioma Symposium;.
has a financial relationship (Professional Services) with University of Miami Int'l Mesothelioma Symposium;.
has a financial relationship (Professional Services) with Johnson & Johnson Global Services;.
has a financial relationship (Professional Services) with Ideology Health LLC;.
has a financial relationship (Professional Services) with Antoni van Leeuwenhoek Kanker Instituut;.
has a financial relationship (Professional Services) with AstraZeneca;.

Anna Matynia

has no relevant financial relationships to disclose at this time.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.

Howard McLeod

has a financial relationship (Independent contractor) with Viecure;.
has a financial relationship (Stock) with Clarified Precision Medicine;.
has a financial relationship (Stock Options) with Vyant Bio;.
has a financial relationship (Stock) with Genovation;.

Christopher Nevala-Plagemann, MD, MSCI

has no relevant financial relationships to disclose at this time.

Sagar Patel, MD

has a financial relationship (Grant Or Contract) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with Medexus;.
has a financial relationship (Grant Or Contract) with CareDx;.

Mark Pegram, MD

has no relevant financial relationships to disclose at this time.

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Sanofi;.

Deepika Sirohi, MD

has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with LOXO/ Eli Lilly;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Relay Therapeutics;.

Umang Swami, MD, MS

has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Seattle Genetics;.

Christos Vaklavas, M.D., Associate Professor

has no relevant financial relationships to disclose at this time.

Theresa Werner, MD

has a financial relationship (Other) with Mersana Therapeutics;.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by independent medical education grants from the following companies:

  • SeaGen
  • Janssen Biotech
  • Pfizer
  • Gilead Sciences

 

Available Credit

  • 9.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$350.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $350

Non-physician HCP (non-industry) - $250

Industry representatives - $850

Fellow or resident - $50

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.